SCHEMBL3403186

SCHEMBL3403186

CC(C)(C)OC(=O)N1CC(Nc2nc(Cl)nc(N3CCOCC3)c2[N+](=O)[O-])C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
PIK3CA P42336 6/20 0.39
PIK3R1 P27986 3/20 0.39
MTOR P42345 5/20 0.38
PIK3CG P48736 3/20 0.38
ATR Q13535 2/20 0.38
AURKB Q96GD4 1/20 0.38
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CHRM3 P20309 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
BTK Q06187 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811944 0.92 PIK3CA (0.44) ALDH1A1MAPTLMNAPIK3CAMTOR
SCHEMBL1693887 0.89 ALDH1A1 (0.44) ALDH1A1MAPTLMNAPIK3CAMTOR
SCHEMBL3399369 0.87 PIK3CA (0.38) ALDH1A1MAPTLMNAPIK3CAPIK3R1
SCHEMBL3403790 0.85 PIK3CA (0.43) PIK3CAPIK3R1MTORPIK3CGATR
SCHEMBL3407918 0.82 ACKR3 (0.41) ALDH1A1MAPTLMNAPIK3CAMTOR
SCHEMBL1694107 0.79 PDE4A (0.52) ALDH1A1MAPTLMNASMN1; SMN2CHRM3
SCHEMBL16037131 0.78 BTK (0.47) PIK3CAMTORPIK3CGATRAURKB
SCHEMBL16037130 0.78 BTK (0.47) PIK3CAMTORPIK3CGATRAURKB
SCHEMBL16037151 0.78 BTK (0.47) PIK3CAPIK3R1MTORPIK3CGATR
SCHEMBL3401953 0.77 PIK3CA (0.49) ALDH1A1MAPTPIK3CAMTORPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD ALDH1A1 3181/4885MAPT 2266/4885LMNA 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.